A method for predicting or prognosticating the response of individuals with multiple sclerosis to treatment with IFNβ, kit or device, and uses.

Provided are anti-IFNAR1 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Provided are antibodies or fragments thereof having binding specificity to the human interferon alpha and beta receptor subunit 1 (IFNAR1) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.

A spectrally filtered photodiode pair includes a substrate having a first photodiode and a second photodiode, wherein the first photodiode is positioned adjacent to the second photodiode. The spectrally filtered photodiode pair further includes a first spectral filter positioned over the first photodiode and a second spectral filter positioned over the second photodiode. The first and second spectral filters comprise particular absorbing dye compositions described herein, selected to filter preselected wavelengths of light. The spectrally filtered photodiode pair can be useful in sensors, particularly when rapid and low-concentration detection is needed.

The invention provides novel methods of determining or comparing potency of a test interferon relative to rSIFN-co (an interferon having therapeutic effects on solid tumors); methods of establishing substantial equivalence between a test interferon and rSIFN-co; as well as methods for determining potency of a test interferon, kits for determination of such methods, and an interferon or an interferon substitute having said activities.

Provided are antibodies or fragments thereof having binding specificity to the human interferon alpha and beta receptor subunit 1 (IFNAR1) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as provided, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.

The invention relates to a method for predicting the clinical response to a therapy based on the administration of mesenchymal stem cells (MSCs) in a patient suffering from an immune-mediated inflammatory disease. The invention also relates to methods of personalised medicine as well as to therapeutic uses of MSCs in a patient suffering from an immune-mediated inflammatory disease.

Provided herein is a reporter system for identifying a cytokine receptor modulator and uses thereof.

The present invention relates to a method of predicting assessing or monitoring the sensitivity of a subject having a cancer to an immunotherapy, and to corresponding kits. The method of predicting, assessing or monitoring the sensitivity of a subject having a tumor to an immunotherapy typically comprises a step a) of determining, in a biological sample from said subject, the presence, absence or expression level of at least one biomarker, for example at least two biomarkers, and when the expression level is determined a step b) of comparing said expression level to reference expression level(s) or to reference expression ratio(s), thereby predicting, assessing or monitoring whether the subject having a tumor is responsive or resistant to the proposed immunotherapy.

The present invention relates to a composition for diagnosis of pancreatic diseases, more specifically, to a composition which can diagnose pancreatic cancer, a kit for diagnosis comprising the same, and a method of providing information for diagnosis using the composition.

The present invention can accurately predict or identify the risk of pancreatic cancer, and moreover, can diagnose pancreatic cancer by effectively distinguishing pancreatic cancer from different types of cancer. In addition, in the present invention, it is possible to diagnose pancreatic cancer simply and rapidly through a non-invasive method by using monocytes obtained from blood, serum or plasma obtained from an individual.